Iran J Pediatr 2016 August 264e3975 Published online 2016 May 15 doi 105812ijp3975 Research Article Comparison Oral Acetaminophen Versus Ibuprofen Premature Infants With Patent Ductus Arteriosus Mohammad Mehdi Bagheri1 Pedram Niknafs1 Fatemeh Sabsevari1 Mohammad Hosein Torabi1 Bahareh Bahman Bijari1 Elahe Noroozi1 Hamid Mossavi1 1Afzalipour Medical Center Kerman University Medical Sciences Kerman IR Iran Corresponding author Fatemeh Sabsevari Afzalipour Medical Center Kerman University Medical Sciences Kerman IR Iran Tel 989131951947 Email fasabzvarigmailcom Received 2015 October 30 Revised 2016 January 28 Accepted 2016 February 05 Abstract Background Patent ductus arteriosus PDA common cause morbidity The aim study compare eﬃcacy oral Acetaminophen oral Ibuprofen closure patent ductus arteriosus PDA preterm infants Objectives This study demonstrated signiﬁcant diﬀerence treatment PDA oral Ac etaminophen oral Ibuprofen preterm neonates Patients Methods This clinical trial randomized study enrolled 120 infants gestational age 37 weeks ad mitted neonatal intensive care unit Afzalipour hospital Kerman Iran 2014 PDA conﬁrmed echocardiographically The trial registered Iranian registry clinical trials Reg No 25542 Sixtyseven infants received oral Acetaminophen 15mgkg hours days 62 infants received Ibuprofen initial dose 20 mgkg followed 10 mgkg 24 48 hours To evaluate eﬃcacy treatment second echocardiography completing treatment Results After ﬁrst course treatment PDA closed 55 821 patients received oral Acetaminophen vs 47 758 given oral Ibuprofen P 038 After second course treatment PDA closed 50 oral Acetaminophen group 733 oral Ibuprofen group P 021 Conclusions This study demonstrated signiﬁcant diﬀerence treatment PDA oral Ac etaminophen oral Ibuprofen preterm neonates Oral Ibuprofen eﬀectively close PDA unfortunately associated adverse eﬀects limiting utility studied alternative drug similar eﬃcacy adverse eﬀects This study recommends Acetaminophen minimal complications treatment PDA preterm neonates instead Ibuprofen Keywords Patent Ductus Arteriosus PDA Neonatal Intensive Care Unit NICU Acetaminophen Ibuprofen Echocardiography 1 Background Patent ductus arteriosus PDA common preterm infants incidence 30 low birth weight infants Bwt 1500 g 1 50 extremely low birth weight ones Bwt 1000 g 2 Subsequently prolonged ductal patency preterm infants linked severe respiratory distress syndrome RDS prolonged assisted ventilation pul monary hemorrhage bronchopulmonary dysplasia BPD necrotizing enterocolitis NEC renal impairment intraventriculurhemorrhage IVH periventricular leuko malacia PVL cerebral palsy death 3 Taking aforementioned associations sideration appreciation hemodynamic eﬀects large lefttoright shunt ductus certain morbidities caused excessive blood ﬂow lungs ischemia led practitioners adopt strate gies closing ductus Currently ﬁrst choice treatment PDA med ical primarily Indomethacin Ibuprofen These drugs cyclooxygenase inhibitors blocking conversion arachidonic acid prostaglandins 4 The treatment success Ibuprofen manage ment PDA reported 70 85 5 The adverse eﬀects peripheral vasoconstric tion gastrointestinal bleeding perforation decreased platelet aggregation hyperbilirubinemia renal fail ure reported cyclooxygenase inhibitors 6 Acetaminophen acts inhibiting activity prostaglandin synthase peroxidase region en zyme 7 Recent studies shown Acetaminophen treat PDA preterm infants good eﬃcacy eﬀects unlike cyclooxygenase inhibitors 8 When drug treatment fails contraindicated clini cians resort surgical intervention risk operation preterm infants high Copyright 2016 Growth Development Research Center This openaccess article distributed terms Creative Commons AttributionNonCommercial 40 International License httpcreativecommonsorglicensesbync40 permits copy redistribute material noncommercial usages provided original work properly cited Bagheri MM et al To determine oral Acetaminophen ﬁrst line alternative drug PDA preterm infants conducted randomized trial com pare eﬃcacy safety level Ibuprofen 2 Objectives This study demonstrated signiﬁcant diﬀerence treatment PDA oral Ac etaminophen oral Ibuprofen preterm neonates 3 Patients Methods The study performed neonatal intensive care unit NICU Afzalipour medical center Kerman Iran tween July November 2014 This trial approved ethics committee infants enrolled study parental consent obtained The enrollment criteria included gestational age 37 weeks postnatal age equal teen days echocardiographically diagnosed PDA fol lowing echocardiographic detection duct size 15 mm left atrium aorta ratio 12 The exclusion criteria follow 1 major congen ital heart disease 2 conﬁrmed sepsis 3 intraventricular hemorrhage grade II IVH basis Volpe staging 4 platelet count 50000mm3 5 severe coagulopathy liver dysfunction 6 presence major congenital chromosomal abnormalities 7 severe asphyxia birth Apgar score 5 minute ﬁve pH 7 ABG 8 necrotizing enterocolitis NEC basis Bell staging 9 tendency bleeding revealed hematuria blood endotracheal gastric aspirate stools oozing puncture sites 10 urine output 1 mLkghour serum creatinine 16 mgdL 11 retionpathy prematu rity Before treatment patients evalu ated complete blood count serum creatinine blood urea nitrogen urine output bilirubin levels cranial ultra sonography twodimensional color Doppler echocar diography 4MH2 transducer model MEDISON AC CUVIlXV 100 South Korea The participants randomly assigned 1 1 ratio oral Acetaminophen Ibuprofen groups ing cards Doctors nurses blind pedi atric cardiologist charge patients blinded treatment Infants received oral Acetaminophen Acetaminophen suspension Hakim 5 mL 120 mg dose 15 mgkg 6 hours 3 days oral Ibuprofen Ibuprofen sus pension Exir 5 mL 100 mg initial dose 20 mgkg followed 10 mgkg 24 48 hours Both Acetaminophen Ibuprofen adminis tered orogastrictube ﬂushed 1 2 mL sterile water ensure delivery drug Minimal enteral feeding attempted infants second day life patients continued current enteral feeding regimen study At beginning study daily oral intake ranged 10 60 mLkg patients groups For infants enrolled study ﬂuid intake started 60 80 mLkgday consistently days increased increments 20 mLkgday maximum 150 mLkgday During treatment drug safety factors sessed daily If birth weight 2 eye ex amination conducted 4 weeks birth Occurrence exclusion criteria prompt stopping treat ment The success rate deﬁned closed duct echocardiography complete course drugs Secondary outcomes safety drugs adverse events oliguria IVH tendency bleeding NEC death 31 Statistical Analyses A study group 57 patients needed study facilitate detecting diﬀerence 25 percentage points closure rate oral Ac etaminophen Ibuprofen groups assuming closure rate 85 oral Ibuprofen P 005 power 50 The study terminated diﬀerence 25 main outcome Continuous data given mean SD Diﬀerences groups determined ttest paramet ric continuous data Fishers exact test categorical data A new drug considered eﬀective known drug P 005 diﬀerence groups SPSS software version 20 statisti cal analyses 4 Results Among 160 patients enrolled study signiﬁcant PDA inclusion criteria ﬁnally 31 patients excluded The study ﬂow chart demonstrated Fig ure 1 2 Iran J Pediatr 2016 264e3975 Bagheri MM et al Figure 1 Study Flow Chart No signiﬁcant diﬀerence observed clinically tween groups baseline The clinically character istic ﬁndings preterm infants summarized Ta ble 1 After ﬁrst course treatment PDA completely closed 55 821 infants Acetaminophen group compared 47 758 Ibuprofen group signiﬁcant diﬀerence treatments P 0381 In oral Ibuprofen group ﬁfteen 242 patients required second course drug therapy compared 179 patients oral Acetaminophen group After second course drugs closure rates 50 patients Acetaminophen group compared 733 seventeen patients Ibuprofen group signiﬁcant diﬀerence P 0212 Finally closure rates courses treatment 91 oral Acetaminophen group 903 oral Ibuprofen group Table 2 Table 1 Clinical Characteristica Characteristics Acetaminophen Ibuprofen P Value Gestational age wk 3153 231 317 224 069 Age d 285 128 342 212 0098 Birth weight Kg 164626 5914 164262 5846 0965 Gender No Female Male Normal vaginal delivery NVD No 31 463 36 537 29 468 0954 33 532 20 303 15 242 0438 Respiratory score unit 528 204 522 175 0864 Surfactante No 37 552 29 468 0337 aValues expressed mean SD indicated 5 Discussion Ductal constrict stimulated rapid postnatal increase arterial oxygen tension decrease va Iran J Pediatr 2016 264e3975 3 160 Preterm Infants Signiﬁcant PDA1 DiedBefore Completed Treatment9 DiedBefore Completed TreatmentTreatmentTreatmentExclusionCriteriaExclusionCriteriaOral AcetaminophenN 67Oral IbuprofenN 71IVH Grade IV 2Died 2Oral IbuprofenN 62Oral AcetaminophenN 79IVH Grade III 1Sepsis 1Rop 1Died 9 Bagheri MM et al Table 2 Outcomes According Each Treatmenta PDA closure rate ﬁrst course PDA closure rate second course Acetaminophenb Ibuprofenc P Value 55 821 45 758 0381 6 50 11 733 0212 Total PDA closure rate 61 91 56 903 0885 aValues expressed No bn 67 cn 62 sodilators including prostaglandin E2 9 Prostaglandin synthetase diﬀerent activ ities including cyclooxygenase peroxidase Ac etaminophen inhibits prostaglandin synthesis peroxides segment 7 Ibuprofen cyclooxygenase inhibitor 10 Some studies conducted Acetaminophen treatment PDA preterm infants Ibuprofen eﬀective contraindicated Hammerman et al ﬁrst time showed oral Acetaminophen eﬀective ﬁve patients large hemodynamically signiﬁcant PDA failed contraindications Ibuprofen therapy Ductal closure achieved treated infants 8 Also series preterm neonates treated Ac etaminophen signiﬁcant PDA contraindi cations Ibuprofen reported Terrin 11 Ac etaminophen ﬁrst choice treatment PDA preterm infants ﬁve infants successfully treated 12 Ibuprofen Acetaminophen compared clinical trials The trial conducted Oncel et al com pared eﬃcacy safety oral Acetaminophen oral Ibuprofen closure PDA 90 preterm infants gestational age equal thirty weeks gestation After ﬁrst course treatment PDA closed 775 31 45 patients infants assigned oral Ibuprofen group vs 725 29 45 patients oral Ac etaminophen group P 06 13 The second study Dang et al comparing oral Acetaminophen Ibuprofen treatment 160 preterm PDA infants The results demonstrated signif icant diﬀerence Acetaminophen Ibuprofen 14 Recent Small case series suggested ac etaminophen alternative cyclooxygenase hibitor PDA management role agent management preterm infants PDA remains determined As aforementioned studies sug gested order generalize conclusions nec essary run randomized analysis multiple center There articles comparing oral Ibuprofen oral Acetaminophen The ﬁrst performed Turkey enrolling neonates 30 weeks study China neonates 34 weeks In contrast enrolled neonates 37 weeks Closure rates PDA Oncel et al trial 725 Acetaminophen group 775 Ibuprofen group 13 Furthermore clo sure rates 812 Acetaminophen group 788 Ibuprofen group Dang et al trial 14 Our ﬁndings showed closure rates 821 Ac etaminophen group 758 Ibuprofen group We similar responsiveness PDA drugs This ﬁnding compatible Turkey China trials Thus study supports results demonstrated oral Acetaminophen Ibuprofen eﬀective sim ilarly closure PDA courses treatment In addition results clearly drugs welltolerated safe signiﬁcant dif ference complications bleeding especially gastrointestinal bleeding NEC IVH liver renal dysfunc tion ROP hyperbilirubinemia This study limitations ﬁrstly PDA fants spontaneously closed time daily echocardiography clinical trial control group necessary Secondly trial com pletely blinded diﬀerent daily doses Ac etaminophen 51 Conclusion Oral Ibuprofen eﬀectively close PDA unfor tunately associated adverse eﬀects limiting utility studied alternative drug similar ef ﬁcacy adverse eﬀects contraindication On basis identical eﬃcacy Ibuprofen Ac etaminophen higher safety Acetaminophen recommended use Acetaminophen drug ﬁrst choice Although demonstrated Acetaminophen utilized drug choice PDA preterm infants good eﬃcacy studies warranted Footnote Authors Contribution Mohammad Mehdi Bagheri cept design critical revision manuscript Pe dram Niknafs concept design critical revision manuscript Fatemeh Sabsevari acquisition data data analysis data interpretation drafting 4 Iran J Pediatr 2016 264e3975 Bagheri MM et al manuscript Bahareh Bahman Bijari critical revision manuscript Elahe Noroozi Mohammad Hosein Torabi design critical revision manuscript Hamid Mossavi critical revision manuscript References 1 Reller MD Rice MJ McDonald RW Review studies evaluating duc tal patency premature infant J Pediatr 19931226S5962 doi 101016s0022347609900440 2 Schmidt B Roberts RS Fanaroﬀ A Davis P Kirpalani HM Nwae sei C et al Indomethacin prophylaxis patent ductus arteriosus risk bronchopulmonary dysplasia analyses Trial Indomethacin Prophylaxis Preterms TIPP J Pedi atr 200614867304 doi 101016jjpeds200601047 PubMed 16769377 3 Benitz WE Treatment persistent patent ductus arteriosus preterm infants time accept null hypothesis J Perinatol 201030424152 doi 101038jp20103 PubMed 20182439 4 Demirel G Erdeve O Dilmen U Pharmacological Management PDA oral versus intravenous medications Curr Clin Pharmacol 20127426370 PubMed 22794156 5 Erdeve O Yurttutan S Altug N Ozdemir R Gokmen T Dilmen U et al Oral versus intravenous ibuprofen patent ductus arterio sus closure randomised controlled trial extremely low birth weight infants Arch Dis Child Fetal Neonatal Ed 2012974F27983 doi 101136archdischild2011300532 PubMed 22147286 6 Zecca E Romagnoli C De Carolis MP Costa S Marra R De Luca D Does Ibuprofen increase neonatal hyperbilirubinemia Pediatrics 200912424804 doi 101542peds20082433 PubMed 19620202 7 Lucas R Warner TD Vojnovic I Mitchell JA Cellular mechanisms ac etaminophen role cyclooxygenase FASEB J 20051966357 doi 101096fj042437fje PubMed 15705740 8 Hammerman C BinNun A Markovitch E Schimmel MS Kaplan M Fink D Ductal closure paracetamol surprising new approach patent ductus arteriosus treatment Pediatrics 20111286e161821 9 Hamrick SE Hansmann G Patent ductus arteriosus preterm infant Pediatrics 20101255102030 doi 101542peds20093506 PubMed 20421261 10 Pourarian S Rezaie M Amoozgar H Shakiba AM Edraki MR Mehdizadegan N HighDose Oral Ibuprofen Treatment Patent Ductus Arteriosus FullTerm Neonates J Pediatr 2015254e2005 11 Terrin G Conte F Scipione A Bacchio E Conti MG Ferro R et al Eﬃ cacy paracetamol treatment patent ductus arteriosus preterm neonates Ital J Pediatr 201440121 doi 10118618247288 4021 PubMed 24555510 12 Yurttutan S Oncel MY Arayici S Uras N Altug N Erdeve O et al A diﬀerent ﬁrstchoice drug medical management patent ductus arteriosus oral paracetamol J Matern Fetal Neonatal Med 20132688257 doi 103109147670582012755162 PubMed 23205872 13 Oncel MY Yurttutan S Erdeve O Uras N Altug N Oguz SS et al Oral paracetamol versus oral ibuprofen management patent duc tus arteriosus preterm infants randomized controlled trial J Pe diatr 201416435104 e1 doi 101016jjpeds201311008 PubMed 24359938 14 Dang D Wang D Zhang C Zhou W Zhou Q Wu H Comparison oral paracetamol versus ibuprofen premature infants patent ductus arteriosus randomized controlled trial PLoS One 2013811e77888 Iran J Pediatr 2016 264e3975 5